TRASTUZUMAB

HER-2 Protein Overexpression

NKGen Biotech, Inc.monoclonal_antibodyPhase 2Dormant

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

7 Active assets in the HER-2 Protein Overexpression cohort.

Asset / Sponsor	Phase	Rating
Zanidatamab Jazz Pharmaceuticals	Phase 2	B
her2 dc1 vaccine H. Lee Moffitt Cancer Center and Research Institute	Phase 2	CCC
Pyrotinib Tianjin Medical University Second Hospital	Phase 2	CCC
Irinotecan Jin-Hee Ahn	Phase 2	CCC
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. NKGen Biotech, Inc.	Phase 1/2	CCC